Dynamics and significance of the antibody response to SARS-CoV-2 infection
Anita S. Iyer,Forrest K. Jones,Ariana Nodoushani,Meagan Kelly,Margaret Becker,Damien Slater,Rachel Mills,Erica Teng,Mohammad Kamruzzaman,Wilfredo F. Garcia-Beltran,Michael Astudillo,Diane Yang,Tyler E. Miller,Elizabeth Oliver,Stephanie Fischinger,Caroline Atyeo,A. John Iafrate,Stephen B. Calderwood,Stephen A. Lauer,Jingyou Yu,Zhenfeng Li,Jared Feldman,Blake M. Hauser,Timothy M. Caradonna,John A. Branda,Sarah E. Turbett,Regina C. LaRocque,Guillaume Mellon,Dan H. Barouch,Aaron G. Schmidt,Andrew S. Azman,Galit Alter,Edward T Ryan,Jason B. Harris,Richelle C. Charles
DOI: https://doi.org/10.1101/2020.07.18.20155374
2020-07-20
Abstract:ABSTRACT BACKGROUND Characterizing the humoral immune response to SARS-CoV-2 and developing accurate serologic assays are needed for diagnostic purposes and estimating population-level seroprevalence. METHODS We measured the kinetics of early antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in a cohort of 259 symptomatic North American patients infected with SARS-CoV-2 (up to 75 days after symptom onset) compared to antibody levels in 1548 individuals whose blood samples were obtained prior to the pandemic. RESULTS Between 14-28 days from onset of symptoms, IgG, IgA, or IgM antibody responses to RBD were all accurate in identifying recently infected individuals, with 100% specificity and a sensitivity of 97%, 91%, and 81% respectively. Although the estimated median time to becoming seropositive was similar across isotypes, IgA and IgM antibodies against RBD were short-lived with most individuals estimated to become seronegative again by 51 and 47 days after symptom onset, respectively. IgG antibodies against RBD lasted longer and persisted through 75 days post-symptoms. IgG antibodies to SARS-CoV-2 RBD were highly correlated with neutralizing antibodies targeting the S protein. No cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies was observed with several known circulating coronaviruses, HKU1, OC 229 E, OC43, and NL63. CONCLUSIONS Among symptomatic SARS-CoV-2 cases, RBD-targeted antibodies can be indicative of previous and recent infection. IgG antibodies are correlated with neutralizing antibodies and are possibly a correlate of protective immunity.